SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:oru-65210"
 

Search: onr:"swepub:oai:DiVA.org:oru-65210" > Improving the manag...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Russi, AlbertoHospital Pharmacy, Veneto Institute of Oncology IOV-I.R.C.C.S., Padua, Italy (author)

Improving the management of high cost anticancer drugs in a health care system

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • 2016-10-18
  • Milan, Italy :Wichtig Publishing,2016
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-65210
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-65210URI
  • https://doi.org/10.5301/grhta.5000243DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:vet swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • As a consequence of the rise in cancer prevalence and in the cost of anticancer drugs, global spending for cancer is increasing rapidly. The aim of this work is to identify and assess some effective cost management parameters and possible strategies to contain expenditure. Cost limitation could be achieved by implementing effective prevention measures and other main actions: diffusion of tailored therapies; systematic postmarketing reviews; cost-effectiveness assessment; accurate treatment choices; more transparent and effective managed entry agreement policies; waste management through personalized dose preparation. To better manage high cost anticancer drugs, oncologists and hospital pharmacists should collaborate in choosing the right drug, for the right patient, at the right time. In addition, besides promoting the use of biosimilars and generic drugs, when different products have a similar clinical effectiveness, a cost-minimization analysis should be performed to identify the best clinical approach at the lowest cost. With the same purpose, verifying real life outcomes by managing postmarketing analyses helps to renegotiate price agreements in a value-for-money model; this could be arranged if the regulatory agencies renegotiate the previously established price within a defined time period. Finally, the centralization of high-cost drug preparation and the implementation of a drug-day (vial sharing) will reduce drug waste.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Damuzzo, VeraSchool of Specialisation in Hospital Pharmacy, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (author)
  • Serena, MartaSchool of Specialisation in Hospital Pharmacy, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (author)
  • Gorreja, FridaHospital Pharmacy, Veneto Institute of Oncology IOV-I.R.C.C.S., Padua, Italy,Nutrition Gut Brain Interactions(Swepub:oru)fga (author)
  • Palozzo, Angelo C.Hospital Pharmacy, Veneto Institute of Oncology IOV-I.R.C.C.S., Padua, Italy (author)
  • Hospital Pharmacy, Veneto Institute of Oncology IOV-I.R.C.C.S., Padua, ItalySchool of Specialisation in Hospital Pharmacy, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (creator_code:org_t)

Related titles

  • In:Global and Regional Health Technology AssessmentMilan, Italy : Wichtig Publishing3:3, s. 155-1582284-2403
  • In:Global & Regional Health Technology Assessment: Italian; Northern Europe and SpanishMilan, Italy : Wichtig Publishing3:3, s. 155-1582283-5733

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view